Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome. We aimed to investigate the efficacy and safety of levoketoconazole in patients with endogenous Cushing's syndrome.
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial / Fleseriu, M.; Pivonello, R.; Elenkova, A.; Salvatori, R.; Auchus, R. J.; Feelders, R. A.; Geer, E. B.; Greenman, Y.; Witek, P.; Cohen, F.; Biller, B. M. K.. - In: THE LANCET DIABETES & ENDOCRINOLOGY. - ISSN 2213-8587. - 7:11(2019), pp. 855-865. [10.1016/S2213-8587(19)30313-4]
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial
Pivonello R.;
2019
Abstract
Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome. We aimed to investigate the efficacy and safety of levoketoconazole in patients with endogenous Cushing's syndrome.File | Dimensione | Formato | |
---|---|---|---|
Efficacy and safety of levoketoconazole.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Accesso privato/ristretto
Dimensione
4.87 MB
Formato
Adobe PDF
|
4.87 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.